Longeveron (LGVN) News Today $0.82 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.84 +0.02 (+3.02%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key PrioritiesMay 20, 2026 | globenewswire.comReviewing Longeveron (NASDAQ:LGVN) & CorMedix (NASDAQ:CRMD)May 15, 2026 | americanbankingnews.comLongeveron Earnings Call: Trial Milestones Amid FDA HurdlesMay 14, 2026 | tipranks.comLGVN Set for Success in 2026May 14, 2026 | finance.yahoo.comLongeveron (LGVN) Q1 2026 Earnings TranscriptMay 14, 2026 | fool.comLongeveron Inc. (LGVN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comLongeveron Announces 2026 First Quarter Financial Results and Provides Business UpdateMay 13, 2026 | globenewswire.comMaxim Group downgrades Longeveron (LGVN)May 12, 2026 | msn.comLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart ...May 11, 2026 | markets.businessinsider.comLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)May 11, 2026 | globenewswire.comLGVN stock slips after hours as FDA flags concerns on rare heart defect trial designMay 10, 2026 | msn.comLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart ...May 10, 2026 | markets.businessinsider.comLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)May 8, 2026 | globenewswire.comLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026May 5, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Longeveron (LGVN)April 16, 2026 | theglobeandmail.comLongeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)April 8, 2026 | globenewswire.comLongeveron Receives Extended Nasdaq Compliance Grace PeriodMarch 25, 2026 | tipranks.comLongeveron Cancels Special Meeting, Reschedules Reverse Split VoteMarch 24, 2026 | tipranks.comLongeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline PressureMarch 19, 2026 | tipranks.comLongeveron Earnings Call: Pivotal Trials, Tight CashMarch 18, 2026 | tipranks.comThe $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t NoticedMarch 18, 2026 | markets.businessinsider.comLongeveron (LGVN) Q4 2025 Earnings Call TranscriptMarch 18, 2026 | finance.yahoo.comLongeveron Inc. (LGVN) Q4 2025 Earnings Call TranscriptMarch 17, 2026 | seekingalpha.comLongeveron Announces 2025 Full Year Financial Results and Provides Business UpdateMarch 17, 2026 | globenewswire.comLongeveron Braces For Q4 Results Following Recent Funding BoostMarch 17, 2026 | benzinga.comLongeveron Braces For Q4 Results Following Recent Funding BoostMarch 17, 2026 | benzinga.comEarnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 ResultsMarch 16, 2026 | finance.yahoo.comLongeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026March 12, 2026 | markets.businessinsider.comLongeveron Announces Closing of Private Placement of up to $30 MillionMarch 11, 2026 | globenewswire.comA $30 Million Reason to Buy Penny Stock Longeveron TodayMarch 11, 2026 | finance.yahoo.comLongeveron secures $15M financing with potential for additional $15M tied to trial milestonesMarch 10, 2026 | msn.comLGVN Secures Operations Through Crucial TestMarch 10, 2026 | msn.comLongeveron Inc. Class AMarch 10, 2026 | cnn.comLongeveron Announces Private Placement of up to $30 MillionMarch 10, 2026 | markets.businessinsider.comLongeveron jumps 70.7% as investors react to up to $30M private placement financingMarch 10, 2026 | quiverquant.comQTrial Results from LGVN Continue to ImpressFebruary 26, 2026 | finance.yahoo.comLongeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem CellFebruary 25, 2026 | globenewswire.comLGVN Announces New CEO and Cost CutsFebruary 17, 2026 | finance.yahoo.comLongeveron Inc. Appoints Stephen H. Willard as New CEO, Succeeding Than PowellFebruary 13, 2026 | quiverquant.comQLongeveron® Appoints Stephen H. Willard as Chief Executive OfficerFebruary 13, 2026 | globenewswire.comLongeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher ProgramFebruary 5, 2026 | globenewswire.comLongeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)January 29, 2026 | globenewswire.comLongeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)January 26, 2026 | markets.businessinsider.comLongeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026December 29, 2025 | finance.yahoo.comLongeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026December 29, 2025 | globenewswire.comLongeveron granted US patent for method of treating female sexual dysfunctionDecember 17, 2025 | msn.comLongeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell TherapyDecember 17, 2025 | markets.businessinsider.comLongeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) ForumDecember 4, 2025 | markets.businessinsider.comLongeveron granted Canadian patent covering laromestrocel administrationDecember 2, 2025 | msn.comLongeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with InflammagingDecember 2, 2025 | globenewswire.com Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LGVN Media Mentions By Week LGVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGVN News Sentiment▼0.930.47▲Average Medical News Sentiment LGVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGVN Articles This Week▼143▲LGVN Articles Average Week Get the Latest News and Ratings for LGVN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Longeveron and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ENTX News DWTX News ZSQR News HYFT News FLNA News PYRGF News ACTU News IMA News PDSB News TIL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGVN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
